Last reviewed · How we verify
NCT03616951
Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT
trial in Renal Neoplasm With Metastasis in 60 participants. Status unknown.
1 January 2023
Quick facts
| Lead sponsor | University of Aarhus |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 January 2018 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Denmark |
Conditions studied
- Renal Neoplasm With Metastasis — all drugs for Renal Neoplasm With Metastasis →
- Response Evaluation Criteria in Solid Tumors — all drugs for Response Evaluation Criteria in Solid Tumors →
Sponsor
University of Aarhus
Who can join
18 and older, any sex, with Renal Neoplasm With Metastasis or Response Evaluation Criteria in Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The incidence of renal cancer in Denmark is approximately 900 new cases per year. Untreated, the 5-year survival rate for metastatic renal cancer (mRCC) is 2%. Development of angiogenesis inhibitors (AI) and check-point immunotherapy (CPI) has improved survival. Treatment efficacy is evaluated by CT scans, using RESIST 1.1 (Response Evaluation Criteria in Solid Tumors). However, progressin in patients with mRCC treated with AI or CPI is difficult to characterize at the right time, using the RECIST 1.1. Therefore approximately 50 % of the patients are 'lost' to further treatment at the time of progression and die. The investigators aim to evaluate if functional imaging parameters using spectral CT-techniques can detect treatment failure earlier, or more accurate, than routine CT. This could help us develop a new set of response evaluation criteria for functional imaging, giving a more precise assessment of treatment effect in patients with mRCC treated with AI and CPI.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
Drljevic-Nielsen A, Donskov F, Mains JR, Andersen MB, et al · · 2022 · cited 6× · PMID 34910540 · DOI 10.2214/ajr.21.26911
Verify or expand the search:
- PubMed search for NCT03616951
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Aarhus trials
Trials by the same sponsor.
- NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
- NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
- NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
- NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03616951 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
- Last refreshed: 24 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03616951.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing